tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Sarcoidosis D012507 13 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Hyperglycemia D006943 21 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Skin Neoplasms D012878 12 associated lipids
Burns D002056 34 associated lipids
Inflammation D007249 119 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Fatty Liver D005234 48 associated lipids
Cataract D002386 34 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Precancerous Conditions D011230 48 associated lipids
Postoperative Complications D011183 5 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Heart Failure D006333 36 associated lipids
Angioedema D000799 6 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Hydronephrosis D006869 4 associated lipids
Trypanosomiasis D014352 5 associated lipids
Alopecia D000505 14 associated lipids
Liver Diseases D008107 31 associated lipids
Corneal Diseases D003316 13 associated lipids
Testicular Diseases D013733 15 associated lipids
Facial Dermatoses D005148 7 associated lipids
Hypersensitivity D006967 22 associated lipids
Osteosarcoma D012516 50 associated lipids
Acne Vulgaris D000152 35 associated lipids
Urination Disorders D014555 9 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Vision Disorders D014786 10 associated lipids
Multiple Myeloma D009101 13 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Melanoma D008545 69 associated lipids
Hematologic Diseases D006402 3 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Osteoporosis D010024 12 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Kidney Diseases D007674 29 associated lipids
Hematuria D006417 13 associated lipids
Weight Gain D015430 101 associated lipids
Brain Diseases D001927 27 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Infection D007239 6 associated lipids
Abnormalities, Multiple D000015 13 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Glioma D005910 112 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Bone Diseases D001847 4 associated lipids
Leukemia P388 D007941 43 associated lipids
Ulcer D014456 16 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Obesity D009765 29 associated lipids
Thrombosis D013927 49 associated lipids
Bradycardia D001919 13 associated lipids
Hemorrhage D006470 15 associated lipids
Proteinuria D011507 30 associated lipids
Lymphoma D008223 18 associated lipids
Femur Head Necrosis D005271 5 associated lipids
Alzheimer Disease D000544 76 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Eye Diseases D005128 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Qin J et al. Radiological and clinical findings of 25 patients with invasive pulmonary aspergillosis: retrospective analysis of 2150 liver transplantation cases. 2012 Br J Radiol pmid:22496071
Anoopkumar-Dukie S et al. Mitochondrial modulation of oxygen-dependent radiosensitivity in some human tumour cell lines. 2009 Br J Radiol pmid:19366737
Murphy GJ et al. Randomized clinical trial of the effect of microemulsion cyclosporin and tacrolimus on renal allograft fibrosis. 2003 Br J Surg pmid:12808614
Middleton SJ et al. Adult small intestinal transplantation in England and Wales. 2003 Br J Surg pmid:12808622
Morris-Stiff GJ et al. Sequential changes in plasma selenium concentration after cadaveric renal transplantation. 2004 Br J Surg pmid:14991636
Wilson CH et al. Randomized clinical trial of daclizumab induction and delayed introduction of tacrolimus for recipients of non-heart-beating kidney transplants. 2005 Br J Surg pmid:15856479
Waller JR et al. Effects of the combination of rapamycin with tacrolimus or cyclosporin on experimental intimal hyperplasia. 2002 Br J Surg pmid:12390379
Brook NR et al. Fibrosis-associated gene expression in renal transplant glomeruli after acute renal allograft rejection. 2003 Br J Surg pmid:12905557
Jain S et al. Tacrolimus has less fibrogenic potential than cyclosporin A in a model of renal ischaemia-reperfusion injury. 2000 Br J Surg pmid:11091246
Bicknell GR et al. Differential effects of cyclosporin and tacrolimus on the expression of fibrosis-associated genes in isolated glomeruli from renal transplants. 2000 Br J Surg pmid:11091247
White DJ Immunosuppression for heart transplantation. 1993 Br. J. Biomed. Sci. pmid:7694717
Reichert TE et al. The role of endogenous interleukin-2 in proliferation of human carcinoma cell lines. 1999 Br. J. Cancer pmid:10555752
Andersson Y et al. Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo. 2009 Br. J. Cancer pmid:19773757
Chambers CA Topical tacrolimus for cutaneous lupus erythematosus. 2003 Br. J. Dermatol. pmid:12752154
Ludwig E et al. New treatment modalities for granuloma faciale. 2003 Br. J. Dermatol. pmid:14511001
Vecchietti G et al. Topical tacrolimus (FK506) for relapsing erosive stomatitis in paraneoplastic pemphigus. 2003 Br. J. Dermatol. pmid:12752158
Patel NP et al. Treatment of eosinophilic pustulosis of infancy with topical tacrolimus. 2012 Br. J. Dermatol. pmid:22563626
Aoyama H et al. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment. 1995 Br. J. Dermatol. pmid:8547017
Meingassner JG et al. Pimecrolimus does not affect Langerhans cells in murine epidermis. 2003 Br. J. Dermatol. pmid:14616380
Wilsmann-Theis D et al. Successful treatment of acrodermatitis continua suppurativa with topical tacrolimus 0.1% ointment. 2004 Br. J. Dermatol. pmid:15214910
Lerbaek A and Agner T Facial eruption of molluscum contagiosum during topical treatment of atopic dermatitis with tacrolimus. 2004 Br. J. Dermatol. pmid:15214914
Edmonds EV et al. Nodular prurigo responding to topical tacrolimus. 2004 Br. J. Dermatol. pmid:15214918
Murrell DF et al. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. 2007 Br. J. Dermatol. pmid:17935515
Liao YH et al. Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(-1) ointment and tacrolimus 0.3 mg g(-1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. 2007 Br. J. Dermatol. pmid:17935517
Sugiura H et al. An open study of a lotion formulation to improve tolerance of tacrolimus in facial atopic dermatitis. 2001 Br. J. Dermatol. pmid:11736904
Wu CS et al. FK506 inhibits the enhancing effects of transforming growth factor (TGF)-β1 on collagen expression and TGF-β/Smad signalling in keloid fibroblasts: implication for new therapeutic approach. 2012 Br. J. Dermatol. pmid:22540338
Tennis P et al. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. 2011 Br. J. Dermatol. pmid:21466537
Afshar M et al. The effect of pimecrolimus on innate immunity in subjects with atopic dermatitis: a double-blind, randomized, vehicle-controlled study. 2013 Br. J. Dermatol. pmid:22577776
Calza AM and Lübbe J Tacrolimus ointment-associated alcohol intolerance in infants receiving ethanol-containing medication. 2005 Br. J. Dermatol. pmid:15787832
Rigopoulos D et al. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. 2004 Br. J. Dermatol. pmid:15541087
Clayton TH and Harrison PV Successful treatment of chronic ulcerated necrobiosis lipoidica with 0.1% topical tacrolimus ointment. 2005 Br. J. Dermatol. pmid:15787840
Rodríguez García F et al. Generalized pustular psoriasis successfully treated with topical tacrolimus. 2005 Br. J. Dermatol. pmid:15787845
Danby SG et al. The effect of tacrolimus compared with betamethasone valerate on the skin barrier in volunteers with quiescent atopic dermatitis. 2014 Br. J. Dermatol. pmid:24328907
Weidinger S et al. A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal. 2017 Br. J. Dermatol. pmid:28868633
Charman C A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal - comment. 2017 Br. J. Dermatol. pmid:28858382
Carroll CL et al. Better medication adherence results in greater improvement in severity of psoriasis. 2004 Br. J. Dermatol. pmid:15491434
Wenzel J et al. Successful treatment of recalcitrant Wegener's granulomatosis of the skin with tacrolimus (Prograf). 2004 Br. J. Dermatol. pmid:15491443
Chung BY et al. The proactive treatment of atopic dermatitis with tacrolimus ointment in Korean patients: a comparative study between once-weekly and thrice-weekly applications. 2013 Br. J. Dermatol. pmid:23110605
Kabashima K et al. Treatment of eosinophilic pustular folliculitis (Ofuji's disease) with tacrolimus ointment. 2004 Br. J. Dermatol. pmid:15491457
Esquivel-Pedraza L et al. Treatment of oral lichen planus with topical pimecrolimus 1% cream. 2004 Br. J. Dermatol. pmid:15099380
Aguilar-Bernier M et al. Successful treatment of pruritus with topical tacrolimus in a patient with primary biliary cirrhosis. 2005 Br. J. Dermatol. pmid:15840123
Sorgentini C et al. Lichen striatus in an adult: successful treatment with tacrolimus. 2004 Br. J. Dermatol. pmid:15099383
Dissemond J et al. Pimecrolimus in an adhesive ointment as a new treatment option for oral lichen planus. 2004 Br. J. Dermatol. pmid:15099387
Harth W and Linse R Topical tacrolimus in granuloma annulare and necrobiosis lipoidica. 2004 Br. J. Dermatol. pmid:15099394
Higgins E and Collins P Recurrent bullous erythema multiforme treated with topical tacrolimus 0·1% ointment. 2011 Br. J. Dermatol. pmid:21114481
Pitt M et al. A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema. 2006 Br. J. Dermatol. pmid:16704646
Hashizume H et al. Comparable risk of herpes simplex virus infection between topical treatments with tacrolimus and corticosteroids in adults with atopic dermatitis. 2006 Br. J. Dermatol. pmid:16704659
Simon D et al. Successful treatment of pityriasis lichenoides with topical tacrolimus. 2004 Br. J. Dermatol. pmid:15149526
Mrowietz U et al. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. 1998 Br. J. Dermatol. pmid:9990361
Jain S and Stephens CJ Successful treatment of disseminated granuloma annulare with topical tacrolimus. 2004 Br. J. Dermatol. pmid:15149532
Koguchi-Yoshioka H et al. Intravenous immunoglobulin contributes to the control of antimelanoma differentiation-associated protein 5 antibody-associated dermatomyositis with palmar violaceous macules/papules. 2017 Br. J. Dermatol. pmid:28346662
Ghislain PD et al. Efficacy and systemic absorption of topical tacrolimus used in pyoderma gangrenosum. 2004 Br. J. Dermatol. pmid:15149540
Hoeger PH et al. The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial. 2009 Br. J. Dermatol. pmid:19067708
Griffiths CE Ascomycin: an advance in the management of atopic dermatitis. 2001 Br. J. Dermatol. pmid:11298524
Fujimoto N et al. Facial lichen striatus: successful treatment with tacrolimus ointment. 2003 Br. J. Dermatol. pmid:12653755
Ueda M et al. Successful treatment of amyopathic dermatomyositis with topical tacrolimus. 2003 Br. J. Dermatol. pmid:12653761
Fricain JC et al. Long-term efficacy of topical tacrolimus on oral lesions of chronic graft-versus-host disease. 2007 Br. J. Dermatol. pmid:17300261
Vissers WH et al. Topical treatment of mild to moderate plaque psoriasis with 0.3% tacrolimus gel and 0.5% tacrolimus cream: the effect on SUM score, epidermal proliferation, keratinization, T-cell subsets and HLA-DR expression. 2008 Br. J. Dermatol. pmid:18284400
Ormerod AD Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? 2005 Br. J. Dermatol. pmid:16181449
Lan CC et al. FK506 inhibits tumour necrosis factor-alpha secretion in human keratinocytes via regulation of nuclear factor-kappaB. 2005 Br. J. Dermatol. pmid:16181452
Vukmanovic-Stejic M et al. Relative impact of CD4+CD25+ regulatory T cells and tacrolimus on inhibition of T-cell proliferation in patients with atopic dermatitis. 2005 Br. J. Dermatol. pmid:16181456
Martin-Munoz MF et al. Topical treatment tacrolimus and food allergy. 2005 Br. J. Dermatol. pmid:16181473
Nissi R et al. Altered p53 and Bcl-2 expression in keratinocytes of vulvar lichen sclerosus during pimecrolimus treatment. 2009 Br. J. Dermatol. pmid:19659469
Lan CC et al. FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. 2005 Br. J. Dermatol. pmid:16120133
Alomar A et al. The role of topical calcineurin inhibitors in atopic dermatitis. 2004 Br. J. Dermatol. pmid:15548171
Ständer S et al. Topical pimecrolimus and tacrolimus transiently induce neuropeptide release and mast cell degranulation in murine skin. 2007 Br. J. Dermatol. pmid:17388925
Mashayekhi S et al. The treatment of vulval lichen sclerosus in prepubertal girls: a critically appraised topic. 2017 Br. J. Dermatol. pmid:28244087
Reitamo S et al. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. 2008 Br. J. Dermatol. pmid:18637898
Barbier N et al. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. 2004 Br. J. Dermatol. pmid:14746622
Rubegni P et al. A case of reticular erythematous mucinosis treated with topical tacrolimus. 2004 Br. J. Dermatol. pmid:14746650
Abe R et al. Severe refractory chronic actinic dermatitis successfully treated with tacrolimus ointment. 2002 Br. J. Dermatol. pmid:12452891
Taher ZA et al. Analysis of interleukin-10 levels in lesions of vitiligo following treatment with topical tacrolimus. 2009 Br. J. Dermatol. pmid:19438859
Lonsdale-Eccles AA and Velangi S Topical pimecrolimus in the treatment of genital lichen planus: a prospective case series. 2005 Br. J. Dermatol. pmid:16086755
Undre NA et al. Skin and systemic pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adults with moderate to severe atopic dermatitis. 2009 Br. J. Dermatol. pmid:19076975
Bäumer W et al. Cilomilast, tacrolimus and rapamycin modulate dendritic cell function in the elicitation phase of allergic contact dermatitis. 2005 Br. J. Dermatol. pmid:16029339
Caproni M et al. The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study. 2007 Br. J. Dermatol. pmid:17223872
Bilenchi R et al. Human papillomavirus reactivation following topical tacrolimus therapy of anogenital lichen sclerosus. 2007 Br. J. Dermatol. pmid:17223903
Mashiko M et al. A case of angiolymphoid hyperplasia with eosinophilia successfully treated with tacrolimus ointment. 2006 Br. J. Dermatol. pmid:16536847
Wollenberg A et al. Economic evaluation of maintenance treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis. 2008 Br. J. Dermatol. pmid:18782316
Doss N et al. Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial. 2009 Br. J. Dermatol. pmid:19416227
Thaçi D et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. 2008 Br. J. Dermatol. pmid:18782319
Leung DY et al. Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle-controlled trial. 2009 Br. J. Dermatol. pmid:19416245
Hickey JR et al. Does topical tacrolimus induce lentigines in children with atopic dermatitis? A report of three cases. 2005 Br. J. Dermatol. pmid:15656817
Mancuso G and Berdondini RM Localized scleroderma: response to occlusive treatment with tacrolimus ointment. 2005 Br. J. Dermatol. pmid:15656828
Neckermann G et al. Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981. 2000 Br. J. Dermatol. pmid:10792216
Queille-Roussel C et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. 2001 Br. J. Dermatol. pmid:11260007
Ramsay HM and Harden PN Cyclosporin-induced flushing in a renal transplant recipient resolving after substitution with tacrolimus. 2000 Br. J. Dermatol. pmid:10792253
Rao A and Bunker C Efficacy and safety of tacrolimus ointment 0.1% vs. betamethasone 17-valerate 0.1% in the treatment of chronic paronychia: an unblinded randomized study. 2010 Br. J. Dermatol. pmid:20353455
Ellis C et al. International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. 2003 Br. J. Dermatol. pmid:12694268
Oji V et al. Topical pimecrolimus: a novel therapeutic option for Netherton syndrome. 2005 Br. J. Dermatol. pmid:16225628
Clayton TH et al. Topical tacrolimus for facial psoriasis. 2003 Br. J. Dermatol. pmid:12932257
Burkhart CG and Burkhart CN Tacrolimus and topical steroids: which is more effective? 2004 Br. J. Dermatol. pmid:15606537
Lee DH et al. Pimecrolimus 1% cream for the treatment of steroid-induced rosacea: an 8-week split-face clinical trial. 2008 Br. J. Dermatol. pmid:18363758
Moreno-Arias GA et al. Plasma cell balanitis treated with tacrolimus 0.1%. 2005 Br. J. Dermatol. pmid:16307659
Tzung TY and Wu JC Topical calcineurin inhibitors in treating Jessner's lymphocytic infiltration of the skin: report of a case. 2005 Br. J. Dermatol. pmid:15727667
Poole CD et al. Health-related utility among adults with atopic dermatitis treated with 0.1% tacrolimus ointment as maintenance therapy over the long term: findings from the Protopic CONTROL study. 2009 Br. J. Dermatol. pmid:19754867
Chu CY The use of 1% pimecrolimus cream for the treatment of steroid-induced rosacea. 2005 Br. J. Dermatol. pmid:15727676
Park CW et al. Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis. 2005 Br. J. Dermatol. pmid:15948978
Grassberger M et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. 1999 Br. J. Dermatol. pmid:10468798
Takeuchi S et al. Pruritus of patients with atopic dermatitis in daily life and their experience of therapeutic effects: results of a web-based questionnaire survey. 2015 Br. J. Dermatol. pmid:25421804